Antibodies against Borrelia burgdorferi sensu lato among Adults, Germany, 2008–2011 - Volume 21, Number 1—January 2015 - Emerging Infectious Disease journal - CDC
Volume 21, Number 1—January 2015
Antibodies against Borrelia burgdorferi sensu lato among Adults, Germany, 2008–2011
Lyme borreliosis, the most common tickborne disease in the Northern Hemisphere, is caused by infection with spirochetes of the Borrelia burgdorferi sensu lato (s.l.) complex. Five genospecies are known to be pathogenic for humans: B. burgdorferi sensu stricto (s.s.), B. afzelii, B. garinii, B. bavariensis, and B. spielmanii (1). In Europe, the bacterium is transmitted to humans through the bite of Ixodes ricinus ticks; in eastern Europe, I. persulcatus ticks can also transmit the bacterium.
In Europe, where the most common clinical manifestation of Lyme borreliosis is erythema migrans, followed by Lyme neuroborreliosis and Lyme arthritis (2), data are sparse regarding B. burgdorferi s.l. infection rates and risk factors (3). Persons of all ages are at risk for infection; however, surveillance data and prospective studies in Europe and the United States suggest that children and the elderly are particularly at risk (4–6). Population-based surveillance data suggest that Lyme borreliosis is endemic in eastern Germany: annual incidence is 20–35 cases/100,000 inhabitants (7). Regional differences in incidence are observed, but data cannot be easily compared because of reporting biases and differences in infection awareness.
The limited representativeness and comparability of Lyme borreliosis surveillance data are well documented (8). Under such conditions, population-based serosurveys with high representativeness can provide valid estimates of the force of infection (rate at which susceptible persons acquire Lyme borreliosis) and the lifetime risk for infection; however, seroprevalence estimates do not necessarily represent cases of clinical disease. In a population-based seroprevalence study among 1- to 17-year-old children in Germany, seroprevalence increased cumulatively by age (9). We present data on the prevalence and determinants of B. burgdorferi s.l. seropositivity among adults in Germany during 2008–2011.
Dr. Wilking is an infectious disease epidemiologist in the unit for Gastrointestinal Infections, Zoonoses and Tropical Infections at the Robert Koch Institute. His research interests include population-based disease studies.
We thank Mona Askar for carefully reviewing the manuscript.
This project was funded by the Robert Koch Institute.
- Fingerle V, Schulte-Spechtel UC, Ruzic-Sabljic E, Leonhard S, Hofmann H, Weber K, Epidemiological aspects and molecular characterization ofBorrelia burgdorferi s.l. from southern Germany with special respect to the new species Borrelia spielmanii sp. nov. Int J Med Microbiol.2008;298:279–90.
- Strle F, Stanek G. Clinical manifestations and diagnosis of Lyme borreliosis. Curr Probl Dermatol. 2009;37:51–110.
- Rizzoli A, Hauffe H, Carpi G, Vourc HG, Neteler M, Rosa R. Lyme borreliosis in Europe. Euro Surveill. 2011;16:19906 .
- Bacon RM, Kugeler KJ, Mead PS. Surveillance for Lyme disease—United States, 1992–2006. MMWR Surveill Summ. 2008;57:1–9.
- Berglund J, Eitrem R, Ornstein K, Lindberg A, Ringer A, Elmrud H, An epidemiologic study of Lyme disease in southern Sweden. N Engl J Med.1995;333:1319–24.
- Huppertz HI, Böhme M, Standaert SM, Karch H, Plotkin SA. Incidence of Lyme borreliosis in the Würzburg region of Germany. Eur J Clin Microbiol Infect Dis. 1999;18:697–703.
- Wilking H, Stark K. Trends in surveillance data of human Lyme borreliosis from six federal states in eastern Germany, 2009–2012. Ticks Tick Borne Dis. 2014;5:219–24.
- Ertel SH, Nelson RS, Cartter ML. Effect of surveillance method on reported characteristics of Lyme disease, Connecticut, 1996–2007. Emerg Infect Dis. 2012;18:242–7.
- Dehnert M, Fingerle V, Klier C, Talaska T, Schlaud M, Krause G, Seropositivity of Lyme borreliosis and associated risk factors: a population-based study in children and adolescents in Germany (KiGGS). PLoS ONE. 2012;7:e41321.
- Scheidt-Nave C, Kamtsiuris P, Gosswald A, Holling H, Lange M, Busch MA, German health interview and examination survey for adults (DEGS)—design, objectives and implementation of the first data collection wave. BMC Public Health. 2012;12:730.
- Tomao P, Ciceroni L, D'Ovidio MC, De RM, Vonesch N, Iavicoli S, Prevalence and incidence of antibodies to Borrelia burgdorferi and to tick-borne encephalitis virus in agricultural and forestry workers from Tuscany, Italy. Eur J Clin Microbiol Infect Dis. 2005;24:457–63.
- Hristea A, Hristescu S, Ciufecu C, Vasile A. Seroprevalence of Borrelia burgdorferi in Romania. Eur J Epidemiol. 2001;17:891–6.
- Hassler D, Zoller L, Haude M, Hufnagel HD, Sonntag HG. Lyme borreliosis in an endemic region in Europe: prevalence of antibodies and clinical spectrum [in German]. Dtsch Med Wochenschr. 1992;117:767–74 .
- Carlsson SA, Granlund H, Nyman D, Wahlberg P. IgG seroprevalence of Lyme borreliosis in the population of the Aland Islands in Finland. Scand J Infect Dis. 1998;30:501–3 and.
- Nadelman RB, Hanincova K, Mukherjee P, Liveris D, Nowakowski J, McKenna D, Differentiation of reinfection from relapse in recurrent Lyme disease. N Engl J Med. 2012;367:1883–90 .
Suggested citation for this article: Wilking H, Fingerle V, Klier C, Thamm M, Stark K. Antibodies against Borrelia burgdorferi sensu lato among adults, Germany, 2008–2011. Emerg Infect Dis. 2015 Jan [date cited]. http://dx.doi.org/10.3201/eid2101.140009